Molecular tumor board-guided personalized therapies in biliary tract cancer: a real-world analysis

Introduction: Biliary tract cancer (BTC) represents a major cause of cancer-related mortality worldwide, with a 5-year survival rate of less than 20%. Notably, distinct BTC subtypes, particularly intrahepatic cholangiocarcinoma, exhibit up to 40% actionable targets. This underscores the importance of an early referral to a Molecular Tumor Board (MTB) for the development of individualized, molecular guided therapeutic strategies. This retrospective study aims to evaluate the impact of MTB inclusion, recommended targeted therapies and their subsequent implementation in patients with BTC in a real-world setting.